Fluoroquinolone Antibacterial Drugs: Drug Safety Communication- Risk for possibly permanent nerve damage
FDA Safety [Posted 08/15/2013] http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm365302.htm
Leggi
Giallo
Le Breaking News di colore giallo sono relative a notizie dalle agenzie regolatorie o da società scientifiche: nuovi farmaci, ritiri, eventi avversi rilevanti…
European Medicines Agency – Investigation into GLP-1 based diabetes therapies concluded
No new concerns for GLP-1 therapies identified on the basis of available evidence. 26/07/2013 EMA Press release http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001856.jsp&mid=WC0b01ac058004d5c1
Leggi
FDA alerts companies to stop illegal sale of treatments for diabetes
Includes certain products containing undeclared active pharmaceutical ingredients FDA NEWS RELEASE July 23, 2013 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm362012.htm
Leggi
ADA/EASD Recommendations for Clinicians and People with Diabetes Concerning the Use of Incretin Therapy and Pancreatic Disease
27 giugno 2013 http://easd.org/index.php?option=com_content&view=article&id=172
Leggi
European Medicines Agency – Outcome of review of new safety data on insulin glargine
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2013 EMA/329790/2013 http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500143823
Leggi
Comunicazione AIFA
Precisazione AIFA su Incretine 20/05/2013 http://www.agenziafarmaco.gov.it/it/content/precisazione-aifa-su-incretine-0
Leggi
Comunicato Stampa EMA sull’uso concomitante di medicinali che agiscono sul sistema renina – angiotensina (RAS) (17/05/2013)
http://www.agenziafarmaco.gov.it/sites/default/files/RAS-acting_agents_-_comunicato%20EMA%5B1%5D.pdf
Leggi
European Medicines Agency recommends restricting use of cilostazol-containing medicines
22 March 2013 - EMA/98571/2013 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Cilostazol-containing_medicines/human_referral_000338.jsp&mid=WC0b01ac05805c516f
Leggi
Comunicato Stampa EMA sulle terapie basate sul GLP-1 (incretino-mimetici) nel trattamento del diabete di tipo 2
Agenzia Italiana del Farmaco (AIFA) - 26 marzo 2013 http://www.agenziafarmaco.gov.it/it/content/comunicato-stampa-ema-sulle-terapie-basate-sul-glp-1-incretino-mimetici-nel-trattamento-del-
Leggi
FDA approves Invokana to treat type 2 diabetes
First in a new class of diabetes drugs FDA NEWS RELEASE: 29/3/2013 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm
Leggi